CPC A61K 47/6815 (2017.08) [A61B 5/0515 (2013.01); A61B 5/055 (2013.01); A61K 47/6811 (2017.08); A61K 47/6851 (2017.08); A61K 47/6923 (2017.08); A61P 35/00 (2018.01); C07K 16/2827 (2013.01); C07K 16/2842 (2013.01); C07K 16/2863 (2013.01); C07K 16/2866 (2013.01); C07K 16/32 (2013.01)] | 7 Claims |
1. A bioconjugate comprising:
(a) a superparamagnetic iron oxide nanoparticle functionalized with a first bioorthogonal ligation moiety selected from the group consisting of tetrazine, an azide, a tetrazole, and combinations thereof, wherein the nanoparticle has a diameter of about 4 nm to about 8 nm; and
(b) a glucose oxidase conjugated to the superparamagnetic iron oxide nanoparticle, wherein the glucose oxidase is functionalized with a second bioorthogonal ligation moiety selected from the group consisting of trans-cyclooctene, cyclooctyne, an alkyne, an alkene, photo-DIBO, cyclopropenone, and combinations thereof.
|
2. The bioconjugate of claim 1, further comprising a targeting probe, wherein the targeting probe is the antibody cetuximab, wherein the antibody cetuximab is conjugated to the glucose oxidase.
|